Progressive supranuclear palsy (PSP): treatment
Evidence-based neurology checklist on progressive supranuclear palsy (psp): treatment: Akinetic rigidity and freezing of gait Levodopa Dopamine agonists Rasagiline up to 1mg daily: especially for PSP-PGF Amantadine: up to a maximum of 100mg tid Liposomal Co-enzyme Q10 100mg tid Physical therapy…
Akinetic rigidity and freezing of gait
- Levodopa
- Dopamine agonists
- Rasagiline up to 1mg daily: especially for PSP-PGF
- Amantadine: up to a maximum of 100mg tid
- Liposomal Co-enzyme Q10 100mg tid
- Physical therapy
Dystonia
Myoclonus
Depression
Sialorrhoea
Insomnia
Urinary urgency and incontinence
Other symptoms
Drugs to avoid
Investigational treatments
References
- Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol 2021 (online ahead of print).
- Bluett B, Pantelyat AY, Litvan I, et al. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP Centers of Care. Front Neurol 2021; 12:694872.
- Nuebling G, Hensler M, Paul S, Zwergal A, Crispin A, Lorenzl S. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol 2016; 263:1565-1574.
- Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 2021; 20:182-192.
- Dam T, Boxer AL, Golbe LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 2021; 27:1451-1457.
- And 1 more. Subscribe to see the full list
